In Dynamic Contrast Enhanced MRI there are several steps from the initial signal to obtaining the pharmacokinetic parameters for tumor characterization. The aim of this work was to validate the steps in the flow of data focusing on T1-mapping, Contrast Agent (CA)-quantification and the pharmacokinetical (PK) model, using a digital phantom of a head. In the Digital Phantom tissues are assigned necessary values to obtain both a regular and contrast enhanced (using Parker AIF) representation and simulating an SPGR signal. The data analysis was performed in a software called MICE, as well as the Digital Phantom developed at the department of Radiation Sciences at Umeå University. The method of variable flip angles for the T1-mapping was analyze...
Object: Dynamic contrast enhanced MRI and pharmacokinetic modelling provide a powerful tool for tumo...
Purpose: Quantitative evaluation of dynamic contrast enhanced MRI (DCE-MRI) allows for estimating pe...
Using dynamic contrast-enhanced MRI (DCE-MRI), it is possible to estimate pharmacokinetic (PK) param...
In Dynamic Contrast Enhanced MRI there are several steps from the initial signal to obtaining the ph...
Dynamic Contrast Enhanced MRI is an important technique to assess the pharmacokinetic properties of ...
Background: Dynamic contrast-enhanced MRI (DCE-MRI) has the potential to produce images of physiolog...
The so-called "Kety model" is a two-compartment pharmacokinetic model describing tumor perfusion kin...
The so-called "Kety model" is a two-compartment pharmacokinetic model describing tumor perfusion kin...
This work is focussed on the analysis of breast tumour physiology by pharmacokinetic modelling of dy...
Optimization of experimental settings of dynamic contrast-enhanced magnetic resonance imaging (DCE-M...
A method is presented for the acquisition and analysis of dynamic contrast-enhanced (DCE) MRI data, ...
International audiencePURPOSE: To test the reproducibility and accuracy of pharmacokinetic parameter...
Object: Dynamic contrast enhanced MRI and pharmacokinetic modelling provide a powerful tool for tumo...
Purpose: Quantitative evaluation of dynamic contrast enhanced MRI (DCE-MRI) allows for estimating pe...
Using dynamic contrast-enhanced MRI (DCE-MRI), it is possible to estimate pharmacokinetic (PK) param...
In Dynamic Contrast Enhanced MRI there are several steps from the initial signal to obtaining the ph...
Dynamic Contrast Enhanced MRI is an important technique to assess the pharmacokinetic properties of ...
Background: Dynamic contrast-enhanced MRI (DCE-MRI) has the potential to produce images of physiolog...
The so-called "Kety model" is a two-compartment pharmacokinetic model describing tumor perfusion kin...
The so-called "Kety model" is a two-compartment pharmacokinetic model describing tumor perfusion kin...
This work is focussed on the analysis of breast tumour physiology by pharmacokinetic modelling of dy...
Optimization of experimental settings of dynamic contrast-enhanced magnetic resonance imaging (DCE-M...
A method is presented for the acquisition and analysis of dynamic contrast-enhanced (DCE) MRI data, ...
International audiencePURPOSE: To test the reproducibility and accuracy of pharmacokinetic parameter...
Object: Dynamic contrast enhanced MRI and pharmacokinetic modelling provide a powerful tool for tumo...
Purpose: Quantitative evaluation of dynamic contrast enhanced MRI (DCE-MRI) allows for estimating pe...
Using dynamic contrast-enhanced MRI (DCE-MRI), it is possible to estimate pharmacokinetic (PK) param...